These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 34306974)

  • 1. In Vivo Induction of Regulatory T Cells Via CTLA-4 Signaling Peptide to Control Autoimmune Encephalomyelitis and Prevent Disease Relapse.
    Kim GR; Kim WJ; Lim S; Lee HG; Koo JH; Nam KH; Kim SM; Park SD; Choi JM
    Adv Sci (Weinh); 2021 Jul; 8(14):2004973. PubMed ID: 34306974
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alleviating psoriatic skin inflammation through augmentation of Treg cells via CTLA-4 signaling peptide.
    Lee WS; Nam KH; Kim JH; Kim WJ; Kim JE; Shin EC; Kim GR; Choi JM
    Front Immunol; 2023; 14():1233514. PubMed ID: 37818377
    [TBL] [Abstract][Full Text] [Related]  

  • 3. dNP2 is a blood-brain barrier-permeable peptide enabling ctCTLA-4 protein delivery to ameliorate experimental autoimmune encephalomyelitis.
    Lim S; Kim WJ; Kim YH; Lee S; Koo JH; Lee JA; Yoon H; Kim DH; Park HJ; Kim HM; Lee HG; Yun Kim J; Lee JU; Hun Shin J; Kyun Kim L; Doh J; Kim H; Lee SK; Bothwell ALM; Suh M; Choi JM
    Nat Commun; 2015 Sep; 6():8244. PubMed ID: 26372309
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD226 attenuates Treg suppressive capacity via CTLA-4 and TIGIT during EAE.
    Wang N; Liang S; Jin J; Fang L; Ma Q; Wang X; Song Y; Chen L
    Immunol Res; 2019 Dec; 67(6):486-496. PubMed ID: 31919790
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulation of human T cell responses by dNP2-ctCTLA-4 inhibits human skin and microvessel graft rejection.
    Lim S; Kirkiles-Smith NC; Pober JS; Bothwell ALM; Choi JM
    Biomaterials; 2018 Nov; 183():128-138. PubMed ID: 30165256
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LRR domain of NLRX1 protein delivery by dNP2 inhibits T cell functions and alleviates autoimmune encephalomyelitis.
    Koo JH; Kim DH; Cha D; Kang MJ; Choi JM
    Theranostics; 2020; 10(7):3138-3150. PubMed ID: 32194859
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tyrosine 201 of the cytoplasmic tail of CTLA-4 critically affects T regulatory cell suppressive function.
    Stumpf M; Zhou X; Chikuma S; Bluestone JA
    Eur J Immunol; 2014 Jun; 44(6):1737-46. PubMed ID: 24648182
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A GMCSF-Neuroantigen Tolerogenic Vaccine Elicits Systemic Lymphocytosis of CD4
    Moorman CD; Curtis AD; Bastian AG; Elliott SE; Mannie MD
    Front Immunol; 2018; 9():3119. PubMed ID: 30687323
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PDCD5 negatively regulates autoimmunity by upregulating FOXP3(+) regulatory T cells and suppressing Th17 and Th1 responses.
    Xiao J; Liu C; Li G; Peng S; Hu J; Qu L; Lv P; Zhang Y; Ma D; Chen Y
    J Autoimmun; 2013 Dec; 47():34-44. PubMed ID: 24012345
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MHC-mismatched mixed chimerism augments thymic regulatory T-cell production and prevents relapse of EAE in mice.
    Wu L; Li N; Zhang M; Xue SL; Cassady K; Lin Q; Riggs AD; Zeng D
    Proc Natl Acad Sci U S A; 2015 Dec; 112(52):15994-9. PubMed ID: 26647186
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amelioration of experimental autoimmune encephalomyelitis by β-elemene treatment is associated with Th17 and Treg cell balance.
    Zhang R; Tian A; Zhang H; Zhou Z; Yu H; Chen L
    J Mol Neurosci; 2011 May; 44(1):31-40. PubMed ID: 21246417
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Engineered regulatory T cells expressing myelin-specific chimeric antigen receptors suppress EAE progression.
    De Paula Pohl A; Schmidt A; Zhang AH; Maldonado T; Königs C; Scott DW
    Cell Immunol; 2020 Dec; 358():104222. PubMed ID: 33053469
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modification of the FoxP3 transcription factor principally affects inducible T regulatory cells in a model of experimental autoimmune encephalomyelitis.
    Verhagen J; Burton BR; Britton GJ; Shepard ER; Anderton SM; Wraith DC
    PLoS One; 2013; 8(4):e61334. PubMed ID: 23593464
    [TBL] [Abstract][Full Text] [Related]  

  • 14. S3I-201, a selective stat3 inhibitor, ameliorates clinical symptoms in a mouse model of experimental autoimmune encephalomyelitis through the regulation of multiple intracellular signalling in Th1, Th17, and treg cells.
    Ahmad SF; Ansari MA; Nadeem A; Bakheet SA; Al-Mazroua HA; Alomar HA; Al-Hamamah MA; Attia SM
    Mult Scler Relat Disord; 2023 May; 73():104658. PubMed ID: 36989705
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ruxolitinib attenuates experimental autoimmune encephalomyelitis (EAE) development as animal models of multiple sclerosis (MS).
    Hosseini A; Gharibi T; Mohammadzadeh A; Ebrahimi-Kalan A; Jadidi-Niaragh F; Babaloo Z; Shanehbandi D; Baghbani E; Baradaran B
    Life Sci; 2021 Jul; 276():119395. PubMed ID: 33781828
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Deletion of CTLA-4 on regulatory T cells during adulthood leads to resistance to autoimmunity.
    Paterson AM; Lovitch SB; Sage PT; Juneja VR; Lee Y; Trombley JD; Arancibia-Cárcamo CV; Sobel RA; Rudensky AY; Kuchroo VK; Freeman GJ; Sharpe AH
    J Exp Med; 2015 Sep; 212(10):1603-21. PubMed ID: 26371185
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CTLA-4 controls the thymic development of both conventional and regulatory T cells through modulation of the TCR repertoire.
    Verhagen J; Genolet R; Britton GJ; Stevenson BJ; Sabatos-Peyton CA; Dyson J; Luescher IF; Wraith DC
    Proc Natl Acad Sci U S A; 2013 Jan; 110(3):E221-30. PubMed ID: 23267099
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of IL-2 in the activation and expansion of regulatory T-cells and the development of experimental autoimmune encephalomyelitis.
    Rouse M; Nagarkatti M; Nagarkatti PS
    Immunobiology; 2013 Apr; 218(4):674-82. PubMed ID: 22954711
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Specific T regulatory cells display broad suppressive functions against experimental allergic encephalomyelitis upon activation with cognate antigen.
    Yu P; Gregg RK; Bell JJ; Ellis JS; Divekar R; Lee HH; Jain R; Waldner H; Hardaway JC; Collins M; Kuchroo VK; Zaghouani H
    J Immunol; 2005 Jun; 174(11):6772-80. PubMed ID: 15905518
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunomodulatory effects and improved prognosis of experimental autoimmune encephalomyelitis after O-tetradecanoyl-genistein treatment.
    Castro SB; Junior CO; Alves CC; Dias AT; Alves LL; Mazzoccoli L; Mesquita FP; Figueiredo NS; Juliano MA; Castañon MC; Gameiro J; Almeida MV; Teixeira HC; Ferreira AP
    Int Immunopharmacol; 2012 Feb; 12(2):465-70. PubMed ID: 22245971
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.